Improving beta‐cell secretory function and glycaemia in young‐onset type 2 diabetes: A pilot, 12‐month, randomized trial of a novel, continuous glucose monitor‐guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide. Issue 4 (28th December 2021)